Johnson & Johnson (NYSE: JNJ) today announced new data from the TREMFYA® (guselkumab) Phase 3 QUASAR long-term extension (LTE) study in adults with moderately-to-severely active ulcerative colitis (UC ...

New long-term extension data from the Phase IIb/III QUASAR trial demonstrate that Tremfya (guselkumab) maintains durable ...

"Data from the ASTRO study demonstrate that subcutaneous induction treatment with TREMFYA provides clinically meaningful remission in patients with ulcerative colitis, similar to the effects seen ...

Johnson & Johnson (J&J) has shared positive long-term results from a phase 3 trial of its dual-acting IL-23 inhibitor Tremfya ...

Johnson & Johnson announces new data from Tremfya phase 3 QUASAR LTE study in adults with moderately-to-severely active ulcerative colitis ...

TREMFYA ® demonstrated clinically meaningful ... Findings for dual-acting are limited to in vitro studies that demonstrate guselkumab binds to CD64, which is expressed on the surface of IL ...

Recent years have seen significant advancements in UC treatment, offering renewed hope for patients seeking effective and ...

The European Commission (EC) has granted marketing authorisation for Johnson & Johnson's (J&J) Tremfya (guselkumab) to treat ...

Guselkumab, an IL-23 inhibitor, is effective in reducing signs, symptoms, and structural damage in active PsA, as confirmed by the APEX study. The FDA approved guselkumab in 2020 based on DISCOVER ...

SAN DIEGO - Johnson & Johnson (NYSE: JNJ) announced today that its Phase 3 ASTRO study of TREMFYA® (guselkumab) demonstrated significant clinical remission and endoscopic improvement in adults ...

May 5, 2025 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced new data from the TREMFYA® (guselkumab) Phase 3 QUASAR long-term extension (LTE) study in adults with moderately-to ...